外观
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
人用药注册技术要求国际协调会议
ICH HARMONISED TRIPARTITE GUIDELINE
ICH协调的三方指南
ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK
为限制潜在的致癌风险而对药品中DNA活性(诱变)杂质进行的评估和控制
M7
综合篇之七
Current Step 4 version dated 23 June 2014
当前为第四阶段版本
发布于2014年6月23日
This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
根据ICH流程,本指南由ICH专家工作组更新而来,并已与有关药政机构协商过。在ICH流程第四阶段,建议欧盟、日本和美国的药政机构采用这份最终稿。
——————分割线————————
注意: